The final week of January was yet another big one for biotech, with perhaps the most important development of the week being phase III trial results for Novavax’s COVID-19 vaccine. For the first week of February, today’s article identifies some biotech/pharma stocks worth paying attention to on account of pending data readouts of COVID-19 trials — including for a potential oral COVID-19 vaccine — and FDA decisions. For more, CLICK HERE.
Biotech/Pharma Stocks To Watch In The First Days Of February
- by Alex Clarke

Tags:Biotech StocksCOVID-19COVID-19 TrialsCOVID-19 VaccineFDAFebruary InvestmentsInvestingNovavax COVID-19 VaccinePharma StocksPhase III TrialsStock MarketStocks